Clinical Trial Update: Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update exploring encorafenib, binimetinib, and palbociclib in BRAF-mutant metastatic melanoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)
• Palbociclib (palbociclib)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Melanoma, Metastasis | Phase 1, Phase 2 | Status: UNKNOWN